Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesGemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas
Cancer, 06/02/09
Cassier PA et al. – Gemcitabine-oxaliplatin combination (GEMOX) is active and well tolerated in pretreated pts with metastatic neuroendocrine tumors.
Methods- Study of GEMOX efficacy in treatment of pts with metastatic neuroendocrine tumors
- GEMOX treatment for 20 consecutive pts with progressive disease, most cases after failure of other chemotherapy regimens (median 2 regimens)
- Follow-up for evidence of toxicity, response, and survival
- Exclusion from efficacy analysis of 2 pts chemotherapy-naive at treatment initiation
- Toxicity manageable overall
- Treatment discontinuation due to oxaliplatin-induced neurotoxicity (grade 2) in 6 pts (30%)
- Partial response for 3 (17%) of 18 pts
- Median progression-free survival: 7 mo
- Median overall survival: 23.4 mo
Related Articles
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Relevance Score: 95%
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Journal of Clinical Oncology, 11/13/09
Relevance Score: 93%
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Relevance Score: 93%
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
British Journal of Cancer, 11/18/09
Relevance Score: 91%
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09
Relevance Score: 91%
Today in Endocrine Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Fas Ligand (FasL, Apo-1L/CD95L) Expression and Clinical Outcome in Papillary Microcarcinoma and Papillary Thyroid Carcinomas with Diameter Smaller than 1.5 Centimeters
Experimental and Clinical Endocrinology & Diabetes, 12/19/09
Diagnostic Accuracy of rhTSH Test with Neck Ultrasonography in Differentiated Thyroid Cancer Follow-up
Experimental and Clinical Endocrinology & Diabetes, 12/19/09
Thyroid follicular neoplasm: Analysis by fine needle aspiration cytology, frozen section, and histopathology
Diagnostic Cytopathology, 12/18/09
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance
Cancer Research, 12/20/09
Acyl-CoA Synthetase VL3 Knockdown Inhibits Human Glioma Cell Proliferation and Tumorigenicity
Cancer Research, 12/20/09
Mutant Metabolic Enzymes Are at the Origin of Gliomas
Cancer Research, 12/20/09
Sponsor
Article Search
Sponsor
Sponsor